Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...
Eminent Gold Corp. (TSXV: EMNT) (OTCQB: EMGDF) (FSE: 7AB) ("Eminent" or the "Company") is pleased to announce the assay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback